Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Harris et al. describe a new mouse model for vitiligo, where interfollicular melanocytes are retained and melanocyte-targeting immune responses are simulated, aiding the development of immunomodulatory therapies.

In a mouse model study, transcutaneous auricular vagus nerve stimulation (taVNS) significantly reduced depigmentation in vitiligo, potentially through mechanisms that regulate oxidative stress and inflammation, indicating taVNS's promise as a therapeutic approach for this skin disorder.

This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.

The study found that the combined administration of regulatory T cells and rapamycin improved outcomes in an experimental model of chronic graft-versus-host disease.

This review highlights that alopecia areata is characterized by three immune endotypes, and while JAK inhibitors offer temporary control, upcoming multi-omics diagnostics and immune reprogramming strategies may achieve longer-lasting remission, according to this analysis.

This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.

This study found that inhibiting JAK signaling can unexpectedly trigger hair growth in resting-phase mouse skin, implicating JAK-STAT pathways and oncostatin M in maintaining hair follicle stem cell quiescence.

This study found that deleting Stim1 and Stim2 in mature T regulatory cells disrupts Ca 2+ signaling, preventing their differentiation and leading to severe autoimmune disorders in mice.

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

This study introduced a novel in vitro murine assay using transgenic mice to identify immunomodulatory compounds, which identified 160 potential hits from 4,398 compounds screened.

This study found that prophylactically administering amotosalen-treated allogeneic donor T cells at transplantation significantly improved immune reconstitution and protection against murine cytomegalovirus infection without inducing graft-versus-host disease.

This study suggests that low-dose IL-2 and IL-15 may help restore immune tolerance in alopecia areata by maintaining Treg cell function, presenting a potential new treatment strategy.

In this reported case, an immunosuppressive regimen including tacrolimus and mycophenolate mofetil was associated with a total regression of hidradenitis suppurativa activity over one year, while cyclosporine alone had no effect.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

In this study, topical tacrolimus 0.1% ointment applied to mice skin decreased Vegf and Igf-1 mRNA levels during late anagen but did not alter hair cycling or skin appearance compared to untreated skin.

This study reviewed how neuropeptides and cutaneous innervation play crucial roles in the process of wound healing, suggesting they significantly influence inflammation and tissue repair phases.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

In this study, researchers found that patients with alopecia areata had a significant increase in NKG2D+CD4+ T cell levels in their blood compared to healthy controls.

This study found that in biopsied skin samples of alopecia areata, a lower anagen/telogen ratio was associated with increased T cell infiltration, and enhancing the PD-1/PD-L1 axis may inhibit CD8+T cell infiltration and improve the condition.

This study found that injecting mouse hair follicle-derived mesenchymal stem cells (moMSCORS) into C57BL/6 mice reduced the incidence and severity of type 1 diabetes by modulating immune responses, suggesting potential for therapeutic use due to their immunosuppressive effects.

This review discusses the dynamic behavior of immune cells in skin immune responses using intravital imaging in mice and reports no new clinical results.

This study suggests that local skin inflammation may enhance the deposition of autoantibodies in the skin, potentially affecting the severity of pemphigus lesions in mice.

This study suggests that adding imiquimod to diphenylcyclopropenone treatment significantly improves outcomes for alopecia areata patients who initially do not respond to diphenylcyclopropenone alone.

This study suggests that SOCS3 treatment may effectively inhibit alopecia areata by suppressing CD8+ T cell activity and IFN-γ production.

This review discusses how immune mechanisms contribute to the regeneration and repair of epithelial tissues and highlights their potential role in both disease and therapeutic innovation; it reports no new clinical results.

This case study highlights the importance of early detection and management of pembrolizumab-induced hepatitis, suggesting that early steroid treatment could potentially prevent severe complications.

In this mini-review, recent insights suggest a possible role of type-2-related immunity in diseases like alopecia areata, vitiligo, and localized scleroderma, though whether this immune response benefits or worsens these conditions remains unclear.

This study demonstrated that antigens from the skin bacterium Staphylococcus epidermidis can stimulate CD8+ T cells, which in turn enhance wound healing.

Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.

This review discusses the cutaneous side effects of targeted anticancer therapies, such as rashes and hair changes, but presents no new clinical results.